Medicare Part D: Patients Bear The Cost Of ‘Me Too’ Brand-Name Drugs | Zendy

Nicole Gastala | Zendy; Peter Wingrove | Zendy; Anne H. Gaglioti | Zendy; Stephen Petterson | Zendy; Andrew Bazemore | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Medicare Part D: Patients Bear The Cost Of ‘Me Too’ Brand-Name Drugs

Author(s) -

Nicole Gastala,

Peter Wingrove,

Anne H. Gaglioti,

Stephen Petterson,

Andrew Bazemore

Publication year - 2016

Publication title -

health affairs

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.837

H-Index - 178

eISSN - 2694-233X

pISSN - 0278-2715

DOI - 10.1377/hlthaff.2016.0146

Subject(s) - brand names , medical prescription , medicare part d , prescription drug , business , health care , prescription costs , medicine , health care cost , advertising , marketing , economics , pharmacology , economic growth

Prescription drugs are a major source of US health care expenditure. "Me too" brand-name medications contribute to the cost of drugs, which is substantial for consumers. In 2013 patient copayments averaged 10.5 times more for two commonly prescribed brand-name medications versus generic therapeutic alternatives.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research